HUGE Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	1.20M
Średni wolumen	210 196
Kapitalizacja rynkowa	14.96M
EPS	$0 ( 2024-04-01 )
Następna data zysków	( $0 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.800
ATR14	$0.00200 (0.54%)

Wolumen Korelacja

Długi: 0.08 (neutral)

Krótki: 0.00 (neutral)

Signal:(47.401) Neutral

FSD Pharma Inc Korelacja

10 Najbardziej pozytywne korelacje
APVO	0.948
VGFC	0.944
SHEN	0.943
WKSP	0.943
MBIN	0.941
GMVD	0.938
JRJC	0.934
MIGI	0.933
TREE	0.932
GLPG	0.932

10 Najbardziej negatywne korelacje
IVCB	-0.945
AEYE	-0.941
ALSA	-0.939
MSSA	-0.939
TZPS	-0.939
TZPSU	-0.933
MPRA	-0.932
MLAI	-0.93
VITL	-0.929
VCTR	-0.927

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

FSD Pharma Inc Korelacja - Waluta/Towar

-0.24
( neutral )

-0.23
( neutral )

0.00
( neutral )

-0.45
( neutral )

0.26
( neutral )

FSD Pharma Inc Finanse

Annual	2023
Przychody:	$0
Zysk brutto:	$-2.55M (0.00 %)
EPS:	$-0.470

FY	2023
Przychody:	$0
Zysk brutto:	$-2.55M (0.00 %)
EPS:	$-0.470

FY	2022
Przychody:	$0
Zysk brutto:	$-4.36M (0.00 %)
EPS:	$-0.600

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-1.010

Financial Reports:

No articles found.

FSD Pharma Inc

FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such as depressive disorder; and Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. FSD Pharma Inc. was founded in 1998 and is headquartered in Toronto, Canada.